PHYTOCHEMICAL NANOFORMULATIONS: A PROMISING APPROACH FOR OVERCOMING DRUG RESISTANCE IN CANCER

Dr.R. Sundhararajan[1], Mr. S.G. Raman*[2], Mrs.R. Jothilakshmi[3], Mrs.K. Suganya Sri[2]
1. Principal and Professor, Mohamed Sathak AJ College of Pharmacy
2. Professor in Charge, Mohamed Sathak AJ College of Pharmacy
3. Associate Professor, Mohamed Sathak AJ College of Pharmacy

Abstract:

Phytochemical formulations represent a groundbreaking approach in the fight against drug-resistant cancers. Traditional chemotherapy and targeted therapies often encounter significant obstacles due to the development of drug resistance, which is a major cause of treatment failure and cancer recurrence. Drug resistance can arise from various mechanisms, including drug efflux, alterations in drug targets, enhanced DNA repair, and evasion of apoptosis. To counter these challenges, integrating nanotechnology with phytochemicals offers a promising solution. Phytochemicals, bioactive compounds derived from plants, have demonstrated potent anticancer properties with diverse mechanisms of action. These include inducing apoptosis, inhibiting proliferation, angiogenesis, and metastasis, and modulating various cellular signaling pathways. Despite their potential, the clinical application of phytochemicals has been limited due to poor solubility, stability, and bioavailability. Nano formulations, such as nanoparticles, liposomes, micelles, and dendrimers, can significantly enhance the delivery and efficacy of phytochemicals. Nanoformulations improve the solubility and stability of phytochemicals, enabling better absorption and bioavailability. They can be engineered to target cancer cells specifically, thereby reducing off-target effects and enhancing therapeutic outcomes. Additionally, nanocarriers can be designed to bypass drug efflux pumps, one of the key mechanisms of drug resistance, by facilitating direct intracellular delivery of phytochemicals. This targeted approach ensures a higher concentration of the active compound at the tumor site, increasing the likelihood of overcoming resistance mechanisms. Recent studies have demonstrated the effectiveness of various phytochemical nanoformulations in preclinical models. For instance, curcumin-loaded nanoparticles have shown improved therapeutic efficacy and reduced toxicity in resistant cancer cell lines. Similarly, nanoformulations of resveratrol and epigallocatechin gallate (EGCG) have exhibited enhanced anti-cancer activity through improved delivery and sustained release. Moreover, phytochemical nanoformulations can be utilized in combination with conventional chemotherapeutics to achieve a synergistic effect, potentially reversing resistance and restoring drug sensitivity. This combinatorial approach not only maximizes the therapeutic impact but also minimizes the required dosage of chemotherapeutic agents, thereby reducing adverse side effects. In conclusion, phytochemical nanoformulations offer a promising and innovative strategy to overcome drug resistance in cancer. By enhancing the bioavailability and targeted delivery of phytochemicals, these nanoformulations can effectively circumvent resistance mechanisms, providing a potent adjunct or alternative to conventional cancer therapies. Continued research and

development in this field are essential to translate these promising findings from the laboratory to clinical settings, ultimately improving outcomes for patients with drug-resistant cancers.

Keywords: Phytochemicals, Nanoformulations, Chemotherapy, Bioavailability, Drug resistance.

Introduction:

Cancer remains one of the leading causes of mortality worldwide, with drug resistance posing a significant challenge to effective treatment. Traditional chemotherapy often encounters obstacles such as multidrug resistance (MDR), which limits the efficacy of anticancer agents and leads to treatment failure. In recent years, phytochemicals—bioactive compounds derived from plants—have garnered attention for their potential anticancer properties. However, their clinical application is often hindered by poor bioavailability, instability, and low solubility. To overcome these limitations, the integration of phytochemicals into nanoformulations has emerged as a promising strategy. Phytochemical nanoformulations leverage nanotechnology to enhance the delivery and therapeutic efficacy of plant-derived compounds. These nanoformulations include nanoparticles, liposomes, micelles, and dendrimers, which can encapsulate phytochemicals, thereby improving their solubility, stability, and bioavailability. The nanoscale size of these carriers facilitates better penetration and retention within tumor tissues, known as the enhanced permeability and retention (EPR) effect. This targeted delivery minimizes the adverse effects on healthy cells and reduces systemic toxicity. Moreover, phytochemical nanoformulations can bypass drug resistance mechanisms. For instance, they can evade efflux pumps, which cancer cells often overexpress to expel chemotherapeutic agents. Additionally, these formulations can be designed to release their payload in response to specific tumor microenvironment triggers, such as pH, enzymes, or temperature, ensuring that the phytochemicals exert their therapeutic effects precisely where needed.

The combination of phytochemicals and nanotechnology offers a multifaceted approach to cancer therapy. Phytochemicals such as curcumin, resveratrol, and epigallocatechin gallate (EGCG) have shown potential in preclinical studies when delivered through nanoformulations, exhibiting enhanced anticancer activity and reduced side effects. Furthermore, these nanoformulations can be co-loaded with conventional chemotherapeutic drugs to achieve synergistic effects, overcoming drug resistance more effectively than either approach alone. In summary, phytochemical nanoformulations represent a promising frontier in cancer therapy, offering innovative solutions to overcome drug resistance. By enhancing the delivery and efficacy of phytochemicals, these advanced formulations hold the potential to improve patient outcomes and pave the way for more effective and targeted cancer treatments.

Cancer drug resistance:

Cancer drug resistance occurs when cancer cells adapt to resist the effects of chemotherapy, leading to treatment failure. This resistance can be intrinsic (present before treatment) or acquired (developed during treatment). Mechanisms include:

1. Efflux of Drugs: Cancer cells pump out drugs using proteins like P-glycoprotein.

2. Drug Inactivation: Enzymes within cancer cells degrade or modify the drug.

3. Alteration of Drug Targets: Changes in the molecular targets of drugs reduce their effectiveness.

4. DNA Repair Enhancement: Increased ability of cancer cells to repair DNA damage caused by chemotherapy.

5. Evasion of Apoptosis: Cancer cells avoid programmed cell death, a typical effect of chemotherapy.

Phytochemicals

Phytochemicals are bioactive compounds derived from plants. They exhibit various anticancer properties, such as:

Curcumin from turmeric

Resveratrol from grapes

Epigallocatechin gallate (EGCG) from green tea

Quercetin from onions and apples

These compounds can target multiple pathways involved in cancer progression and resistance.

Nanoformulations

Nanoformulations involve incorporating drugs into nanoparticles to enhance their delivery and effectiveness. Benefits include:

Improved Solubility: Many phytochemicals have poor water solubility, which nanoformulations can improve.

Enhanced Bioavailability: Nanoparticles can enhance the absorption and distribution of phytochemicals in the body.

Targeted Delivery: Nanoparticles can be engineered to specifically target cancer cells, reducing side effects on healthy cells.

Controlled Release: Nanoparticles can provide sustained release of the drug, maintaining therapeutic levels for extended periods.

Promising Approaches

1. Polymeric Nanoparticles: Encapsulating phytochemicals in biodegradable polymers like PLGA (poly(lactic-co-glycolic acid)) for sustained and controlled drug release.

2. Lipid-based Nanoparticles: Using liposomes or solid lipid nanoparticles to improve the solubility and stability of phytochemicals.

3. Dendrimers: Branched nanopolymers that can carry multiple drug molecules, enhancing delivery efficiency.

4. Inorganic Nanoparticles: Gold and silica nanoparticles can be functionalized with phytochemicals for targeted delivery and imaging.

Examples of Phytochemical Nanoformulations

1. Curcumin-loaded nanoparticles: Demonstrated enhanced uptake by cancer cells and improved anticancer efficacy compared to free curcumin.

2. Resveratrol nanoformulations: Showed increased stability and bioavailability, leading to better inhibition of cancer cell growth.

3. EGCG nanoparticles: Provided sustained release and higher therapeutic effectiveness in various cancer models.

Mechanisms of Overcoming Drug Resistance

1. Inhibiting Efflux Pumps: Some phytochemicals can inhibit the function of efflux pumps, allowing higher intracellular concentrations of chemotherapy drugs.

2. Synergistic Effects: Phytochemicals can work synergistically with conventional drugs, enhancing their effectiveness and reducing resistance.

3. Modulation of Apoptosis: Phytochemicals can induce apoptosis in resistant cancer cells by modulating related signaling pathways.

4. Epigenetic Modulation: Certain phytochemicals can alter gene expression in cancer cells, reversing resistance mechanisms.

Polymeric nano particles:

Polymeric nanoparticles (PNPs) used for phytochemical nanoformulations offer a promising approach to overcoming drug resistance in cancer. These nanoformulations leverage the unique properties of polymers and phytochemicals to enhance the delivery, efficacy, and safety of anticancer therapies.

PNPs are nano-sized carriers made from biocompatible and biodegradable polymers. They are designed to encapsulate therapeutic agents, including phytochemicals, to improve their pharmacokinetics and therapeutic index.

Common Polymers Used:

Poly(lactic-co-glycolic acid) (PLGA): Biodegradable, FDA-approved, and widely used for drug delivery.

Polyethylene glycol (PEG): Provides steric stabilization and prolongs circulation time.

Chitosan: Biocompatible and enhances mucoadhesion.

Polycaprolactone (PCL): Offers slow degradation rates, suitable for sustained release formulations.

Phytochemicals:

Phytochemicals are bioactive compounds derived from plants with various therapeutic properties, including anticancer effects. Their natural origin and diverse mechanisms of action make them suitable candidates for cancer therapy. However, they often face challenges such as poor solubility, stability, and bioavailability.

Advantages of Phytochemical-Loaded PNPs:

1. Enhanced Solubility and Stability:

Encapsulation in PNPs improves the solubility and stability of hydrophobic phytochemicals, making them more effective in biological environments.

2. Targeted Delivery:

PNPs can be engineered to target specific cancer cells by modifying their surface with targeting ligands such as antibodies, peptides, or folic acid. This enhances the accumulation of phytochemicals in tumor tissues and reduces off-target effects.

3. Controlled Release:

PNPs allow for controlled and sustained release of phytochemicals, maintaining therapeutic concentrations over extended periods and reducing the frequency of administration.

Gold Nanoparticles (AuNPs):

Gold nanoparticles are nanoscale particles made of gold atoms. They possess unique physical and chemical properties, such as high surface area-to-volume ratio, ease of surface modification, and biocompatibility, making them ideal candidates for drug delivery applications.

Gold Nanoparticles for Phytochemical Nanoformulations:

Advantages of AuNPs in Phytochemical Delivery:

1. Improved Solubility and Stability:

Phytochemicals can be encapsulated or conjugated onto the surface of AuNPs, improving their solubility and stability, thus enhancing their therapeutic efficacy.

2. Targeted Drug Delivery:

AuNPs can be functionalized with targeting ligands, such as antibodies or peptides, to specifically target cancer cells, reducing off-target effects and improving drug accumulation at the tumor site.

3. Enhanced Cellular Uptake:

AuNPs facilitate cellular uptake of phytochemicals by cancer cells, overcoming multidrug resistance mechanisms, such as drug efflux pumps.

4. Combined Therapeutic Modalities:

AuNPs can be used for combination therapy by loading multiple phytochemicals or combining phytochemicals with other therapeutic agents, such as chemotherapeutic drugs or nucleic acids.

Using nanoparticle based combination therapies in overcoming multi drug resistance in cancer:

Nanoparticle-based combination therapies present a compelling strategy for combating multi-drug resistance (MDR) in cancer. By encapsulating multiple drugs within nanoparticles, these therapies can bypass efflux pumps, alter cellular uptake mechanisms, and target multiple pathways simultaneously, effectively overcoming resistance mechanisms. This approach holds significant promise for enhancing the efficacy of cancer treatment and improving patient outcomes in cases of MDR.

Conclusion:

In the relentless battle against cancer, drug resistance remains a formidable challenge, limiting the effectiveness of many traditional chemotherapy agents. However, the emergence of phytochemical nanoformulations has offered a promising avenue to tackle this issue. Through their unique properties and mechanisms, these nanoformulations have shown remarkable potential in overcoming drug resistance in cancer. One of the key advantages of phytochemical nanoformulations lies in their ability to enhance drug delivery to tumor cells. Nanoparticles can be engineered to bypass efflux pumps, which are one of the primary mechanisms of drug resistance in cancer cells. By evading these pumps, phytochemical-loaded nanoparticles can effectively deliver therapeutic agents into cancer cells, thereby overcoming resistance and enhancing the cytotoxic effects of the drugs. Moreover, phytochemical nanoformulations exhibit multi-targeting capabilities, which is crucial for overcoming the heterogeneous nature of cancer and its various resistance mechanisms. Unlike single-target drugs, phytochemicals often act on multiple pathways involved in cancer progression and resistance. By encapsulating these phytochemicals into nanoparticles, their synergistic effects can be maximized, targeting multiple signaling pathways simultaneously and minimizing the likelihood of resistance development. Furthermore, the use of phytochemical nanoformulations offers the advantage of reduced systemic toxicity. Traditional chemotherapy drugs often cause significant side effects due to their non-selective targeting of both cancer and healthy cells. However, by encapsulating phytochemicals into nanoparticles, targeted delivery to tumor sites can be achieved, minimizing damage to healthy tissues and reducing adverse effects. Despite these promising advantages, it is important to acknowledge that challenges remain in the development and optimization of phytochemical nanoformulations. Issues such as scalability, reproducibility, and long-term safety need to be addressed through rigorous preclinical and clinical studies. Additionally, the complex interplay between nanoparticles and the tumor microenvironment requires further investigation to maximize the therapeutic efficacy of these formulations. In conclusion, phytochemical nanoformulations represent a promising strategy for overcoming drug resistance in cancer. Their ability to enhance drug delivery, multi-target cancer cells, and reduce systemic toxicity make them valuable tools in the fight against cancer. With continued research and development, phytochemical nanoformulations have the potential to revolutionize cancer therapy and improve patient outcomes.

References:

1. Abdelmoneem M. A., Mahmoud M., Zaky A., Helmy M. W., Sallam M., Fang J.-Y., et al. (2018). Dual-targeted casein micelles as green nanomedicine for synergistic phytotherapy of hepatocellular carcinoma. *J. Control Release* 287, 78–93. 10.1016/j.jconrel.2018.08.026.
2. Abe S., Otsuki M. (2002). Styrene maleic acid neocarzinostatin treatment for hepatocellular carcinoma. *Curr. Med. Chem. Anticancer Agents* 2, 715–726. 10.2174/1568011023353679.
3. Abotaleb M., Samuel S., Varghese E., Varghese S., Kubatka P., Liskova A., et al. (2018). Flavonoids in cancer and apoptosis. *Cancers* 11, 28. 10.3390/cancers11010028.
4. Al-Otaibi A. M., Al-Gebaly A. S., Almeer R., Albasher G., Al-Qahtani W. S., Abdel Moneim A. E. (2022). Potential of green-synthesized selenium nanoparticles using apigenin in human breast cancer MCF-7 cells. *Environ. Sci. Pollut. Res. Int.* 29, 47539–47548. 10.1007/s11356-022-19166-2.

5. Alphandéry E., Grand-Dewyse P., Lefèvre R., Mandawala C., Durand-Dubief M. (2015). Cancer therapy using nanoformulated substances: Scientific, regulatory and financial aspects. *Expert Rev. Anticancer Ther.* 15, 1233–1255. 10.1586/14737140.2015.1086647.
6. Ashrafizadeh M., Alahmari S., Moradi-Ozarlou M., Mohammadinejad R., Farkhondeh T., Samarghandian S., et al. (2020). Natural products and phytochemical nanoformulations targeting mitochondria in oncotherapy: An updated review on resveratrol. *Biosci. Rep.* 40. 10.1042/BSR20200257.
7. Askar M. A., El Shawi O. E., Abou zaid O. A. R., Mansour N. A., Hanafy A. M. (2021). Breast cancer suppression by curcumin-naringenin-magnetic-nano-particles: *In vitro* and *in vivo* studies. *Tumor Biol.* 43, 225–247. 10.3233/TUB-211506.
8. Assaraf Y. G., Brozovic A., Gonçalves A. C., Jurkovicova D., Line A., Machuqueiro M., et al. (2019). The multi-factorial nature of clinical multidrug resistance in cancer. *Drug Resist Updat* 46, 100645. 10.1016/j.drup.2019.100645.
9. Babaei G., Aziz S. G.-G., Jaghi N. Z. Z. (2021). EMT, cancer stem cells and autophagy; the three main axes of metastasis. *Biomed. Pharmacother.* 133, 110909. 10.1016/j.biopha.2020.110909.
10. Baetke S. C., Lammers T., Kiessling F. (2015). Applications of nanoparticles for diagnosis and therapy of cancer. *Br. J. Radiol.* 88, 20150207. 10.1259/bjr.20150207.
11. Barabadi H., Vahidi H., Mahjoub M., Kosar K., Kamali K., Ponmurugan K., et al. (2020). Emerging antineoplastic gold nanomaterials for cervical cancer therapeutics: A systematic review. *J. Clust. Sci.* 31, 1173–1184. 10.1007/s10876-019-01733-2.
12. Barenholz Y. (2012). Doxil®-the first FDA-approved nano-drug: Lessons learned. *J. Control Release* 160, 117–134. 10.1016/j.jconrel.2012.03.020.
13. Below J., M Das J. (2022). "Vincristine," in *StatPearls* (Treasure Island (FL): StatPearls Publishing;).
14. Benedetto G., Vestal C. G., Richardson C. (2015). Aptamer-functionalized nanoparticles as "smart bombs": The unrealized potential for personalized medicine

and targeted cancer treatment. *Target Oncol.* 10, 467–485. 10.1007/s11523-015-0371-z .

15. Bhattacharya T., Soares G. A. B., Chopra H., Rahman M. M., Hasan Z., Swain S. S., et al. (2022). Applications of phyto-nanotechnology for the treatment of neurodegenerative disorders. *Mater. (Basel)* 15, 804. 10.3390/ma15030804.
16. Borah A., Pillai S. C., Rochani A. K., Palaninathan V., Nakajima Y., Maekawa T., et al. (2020). GANT61 and curcumin-loaded PLGA nanoparticles for GLI1 and PI3K/Akt-Mediated inhibition in breast adenocarcinoma. *Nanotechnology* 31, 185102. 10.1088/1361-6528/ab6d20.
17. Busatto S., Pham A., Suh A., Shapiro S., Wolfram J. (2019). Organotropic drug delivery: Synthetic nanoparticles and extracellular vesicles. *Biomed. Microdevices* 21, 46. 10.1007/s10544-019-0396-7.
18. Cencic A., Chingwaru W. (2010). The role of functional foods, nutraceuticals, and food supplements in intestinal health. *Nutrients* 2, 611–625. 10.3390/nu2060611 .
19. Chan M. M., Chen R., Fong D. (2018). Targeting cancer stem cells with dietary phytochemical - repositioned drug combinations. *Cancer Lett.* 433, 53–64. 10.1016/j.canlet.2018.06.03.
20. Chatterjee D. K., Diagaradjane P., Krishnan S. (2011). Nanoparticle-mediated hyperthermia in cancer therapy. *Ther. Deliv.* 2, 1001–1014. 10.4155/tde.11.72.
21. Chaudhary K., Masram D. T. (2020). "Biological activities of nanoparticles and mechanism of action," in *Model organisms to study biological activities and toxicity of nanoparticles*. Editors Siddhardha B., Dyavaiah M., Kasinathan K. (Singapore: Springer;), 19–34.
22. Chen Q., Li N., Wang X., Yang Y., Xiang Y., Long X., et al. (2022). Mitochondria-targeting chemodynamic therapy nanodrugs for cancer treatment. *Front. Pharmacol.* 13, 847048. 10.3389/fphar.2022.847048.
23. Cherukuri P., Glazer E. S., Curley S. A. (2010). Targeted hyperthermia using metal nanoparticles. *Adv. Drug Deliv. Rev.* 62, 339–345. 10.1016/j.addr.2009.11.006.
24. De Jong W. H., Borm P. J. A. (2008). Drug delivery and nanoparticles: applications and hazards. *Int. J. Nanomedicine* 3, 133–149. 10.2147/ijn.s596.

25. Dhupal M., Chowdhury D. (2020). Phytochemical-based nanomedicine for advanced cancer theranostics: Perspectives on clinical trials to clinical use. *IJN* 15, 9125–9157. 10.2147/IJN.S259628.
26. Dick J. E. (2008). Stem cell concepts renew cancer research. *Blood* 112, 4793–4807. 10.1182/blood-2008-08-077941.
27. Ellinger J., Alajati A., Kubatka P., Giordano F. A., Ritter M., Costigliola V., et al. (2022). Prostate cancer treatment costs increase more rapidly than for any other cancer-how to reverse the trend? *EPMA J.* 13, 1–7. 10.1007/s13167-022-00276-3.
28. Elsayed A. M., Sherif N. M., Hassan N. S., Althobaiti F., Hanafy N. A. N., Sahyon H. A. (2021). Novel quercetin encapsulated chitosan functionalized copper oxide nanoparticles as anti-breast cancer agent via regulating P53 in rat model. *Int. J. Biol. Macromol.* 185, 134–152. 10.1016/j.ijbiomac.2021.06.085.
29. Fischer H. C., ChanNanotoxicity W. C. W. (2007). Nanotoxicity: The growing need for *in vivo* study. *Curr. Opin. Biotechnol.* 18, 565–571. 10.1016/j.copbio.2007.11.008.
30. Frampton J. E. (2020). Liposomal irinotecan: A review in metastatic pancreatic adenocarcinoma. *Drugs* 80, 1007–1018. 10.1007/s40265-020-01336-6.